Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Aclarion, Inc. (ACON – Research Report) yesterday. The company’s shares opened today at $0.36.
According to TipRanks, Vendetti is an analyst with an average return of -0.9% and a 33.80% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Sensus Healthcare, cbdMD, and Biolase.
Aclarion, Inc. has an analyst consensus of Moderate Buy.
See Insiders’ Hot Stocks on TipRanks >>
Based on Aclarion, Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $19.07 thousand and a GAAP net loss of $998.01 thousand. In comparison, last year the company earned a revenue of $18.22 thousand and had a GAAP net loss of $1.63 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aclarion, Inc. (ACON) Company Description:
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.
Read More on ACON:
- Aclarion announces publication of peer-reviewed data in journal on lumbar discs
- Aclarion Announces Closing of $3.0 Million Public Offering
- Aclarion Announces Pricing of $3.0 Million Public Offering
- Aclarion prices 5.175M units at 58c in public offering
- Aclarion, Inc. Clarifies Unfiled Financial Disclosure Status
